• Eli Lilly escalated its legal campaign against black-market retatrutide, filing six new lawsuits against U.S. sellers.
• Targets include compounding pharmacies, medical spas, online sellers accused of marketing unapproved retatrutide for human use.
• Retatrutide remains investigational in Phase 3 trials; no regulator has cleared any retatrutide medicine for human use.
• Lilly also urged platforms, payment firms, shippers, regulators to cut off infrastructure used to sell the drug illegally.
• The company reported more than 14,000 unlawful online listings; it referred more than 200 individuals, entities to U.S. authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE24555) on August 12, 2026, and is solely responsible for the information contained therein.